Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

High prevalence of type 2 diabetes may be linked to excess niacin intake

Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time.

23 Dec 2009

Niacin may not be beneficial for type 2 diabetic patients

High-density lipoprotein (HDL), known as "good" cholesterol, isn't as protective for people with type 2 diabetes, according to research reported in Circulation: Journal of the American Heart Association.

22 Dec 2009

Darbepoetin alfa does not reduce cardiovascular problem in anemic patients on dialysis

An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.

22 Dec 2009

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier™, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French "Conformite Europeenne") certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.

22 Dec 2009

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

Arena Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

22 Dec 2009

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

22 Dec 2009

Cost outweighs benefits of self-monitoring blood glucose test strips

Routine self-monitoring of blood glucose levels by people with type 2 diabetes who are not taking insulin is an ineffective use of health resources as the modest benefits are outweighed by the significant cost of test strips, suggest 2 studies http://www.cmaj.ca/embargo/cmaj091017.pdf and http://www.cmaj.ca/embargo/cmaj090765.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .

22 Dec 2009

Jamie Oliver to receive the 2010 TED Prize

Jamie Oliver, celebrity chef and standard-bearer in the fight against obesity and other diet related issues, has been announced as the recipient of the 2010 TED Prize, an award granting recipients $100,000 and something much bigger - an opportunity to realize a wish to change the world.

22 Dec 2009

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.

22 Dec 2009

Medical experts recognize surgery as legitimate and effective treatment for type 2 diabetes

A first-of-its-kind consensus statement by 50 medical experts from around the world has pronounced surgery to be a legitimate and effective treatment for type 2 diabetes, bringing the procedure a significant step closer to wider use and acceptance.

21 Dec 2009

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin.

19 Dec 2009

UCSF/SFGH project to improve health outcomes among diabetes patients honored

A UCSF/San Francisco General Hospital project that used a novel communication tool to improve health outcomes among diabetes patients was honored recently with a quality leadership award from the California Health Care Safety Net Institute.

18 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

Australia's regenerative medicine company, Mesoblast Limited, today announced significant preclinical trial results showing that the proprietary adult stem cell platform could be an effective treatment for diabetes.

18 Dec 2009

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has enrolled the first seven patients for a randomized, double-blind, placebo-controlled Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot Study seeks to determine whether the application of magnetic fields generated by the Company’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing hemoglobin A1c levels.

18 Dec 2009

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes.

18 Dec 2009

Access to convenience stores can pormote childhood obesity

Childhood obesity is directly related to how close kids live to convenience stores, according to the preliminary findings of a major Canadian study presented at the Entretiens Jacques-Cartier in Lyon, France. The ongoing study is named QUALITY for Quebec Adipose and Lifestyle InvesTigation in Youth.

18 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Scientists at deCODE genetics, Inc. publish in the journal Nature the discovery of a version of a common single-letter variant in the sequence of the human genome (SNP) with a major impact on susceptibility to type 2 diabetes (T2D).

17 Dec 2009

People are more prone to Crohn's disease and ulcerative colitis, explains new research

New research by the University of Adelaide could help explain why some people are more prone to Crohn's disease, ulcerative colitis and other autoimmune diseases.

17 Dec 2009

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

High prevalence of type 2 diabetes may be linked to excess niacin intake

Niacin may not be beneficial for type 2 diabetic patients

Darbepoetin alfa does not reduce cardiovascular problem in anemic patients on dialysis

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Cost outweighs benefits of self-monitoring blood glucose test strips

Jamie Oliver to receive the 2010 TED Prize

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

Medical experts recognize surgery as legitimate and effective treatment for type 2 diabetes

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

UCSF/SFGH project to improve health outcomes among diabetes patients honored

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

Access to convenience stores can pormote childhood obesity

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

People are more prone to Crohn's disease and ulcerative colitis, explains new research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in